Technology evaluation: pegaptanib, Eyetech/Pfizer.
Eyetech Pharmaceuticals and Pfizer are co-developing the anti-vascular endothelial growth factor aptamer, pegaptanib, as an angiogenesis inhibitor for the potential treatment of age-related macular degeneration and diabetic macular edema, in addition to other ocular diseases. Gilead was previously investigating the aptamer for the potential treatment of cancer, however, no data have been published for this indication since 1999.
Vinores
Stanley A
SA
Johns Hopkins Hospital, Wilmer Ophthalmological Institute, 825 Maumenee, 600 N Wolfe Street, Baltimore, MD 21287-9289, USA. svinores@jhmi.edu
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use; D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D015861:Retinal Neovascularization / Q000188:drug therapy; D013329:Structure-Activity Relationship; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism*
D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A